Genetic polymorphisms of <i>CYP2C9</i> and <i>CYP2C19</i> in the Beninese and Belgian populations

Allabi, Aurel Constant; Gala, Jean‐Luc; Desager, Jean‐Pierre; Heusterspreute, Michel; Horsmans, Yves

doi:10.1046/j.1365-2125.2003.01937.x

Cited by 100 publications

(69 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that a higher [49] These are some of the representative population studies from various geographical areas. Differences in the allele frequencies were measured by Fisher exact test NS indicates that there were no significant differences (p [ 0.05) Genetic polymorphism of CYP2C19 911 [60] concentration of omeprazole in PMs results in great gastric acid suppression as compared with EMs [26].…”

Section: Discussionmentioning

confidence: 98%

Genetic polymorphism of CYP2C19 in Maharashtrian population

et al. 2007

View full text Add to dashboard Cite

Inter-individual variability in drug response is well known. Genetic polymorphism in genes encoding drug-metabolizing enzymes results in variation in drug metabolism and in turn drug response. The cytochrome P450 enzymes (CYP) play a central role in the metabolism of many therapeutic agents. CYP2C19 gene polymorphism is widely studied in Caucasians, African, and Oriental populations; however, far less is known about other ethnic groups such as Indians. Indian population is an inter-mixture of the Aryan, Dravidian, Kolarain, and the Mongoloid races. CYP2C19 gene polymorphism is reported in North Indian and South Indian populations yet not much is known about Maharashtrian population of Australoid-Europoid origin residing in Western India. This is the first report on CYP2C19 allele and genotype frequencies in Maharashtrian population. In this study, genotypes of major allelic variants of CYP2C19 gene in 139 unrelated healthy Maharashtrian subjects was determined and their frequencies were compared with previously studied Indian and other populations. Meta-analysis revealed that the study population is distinct from Caucasians, Africans and some of the Asian populations and significant heterogeneity exists among Indian subpopulations.

show abstract

Section: Discussionmentioning

confidence: 98%

Genetic polymorphism of CYP2C19 in Maharashtrian population

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Population diversity CYP2C9*2 and *3 allele frequencies were compared among the sampled populations and also among data previously published for 12 European populations scattered all over the continent from the United Kingdom, 17 Holland, 18 France, 16 Germany, 19 Hungary, 20 Italy, 21 Sweden, 22 Turkey, 12 Belgium, 13 Iran, 14 Spain 11 and the Europeans from the United States of America 23 (Table 4). No significant differences were observed among our five samples in any of the CYP2C9 variants.…”

Section: Validation Studymentioning

confidence: 99%

“…[11][12][13][14][15][16][17][18][19][20][21][22][23] Here we present a descriptive study of the prevalence of the most relevant CYP2C9 polymorphisms, CYP2C9*1 (wild type), CYP2C9*2 and CYP2C9*3, in population samples from both Spain (Basque Country, Catalonia, Central Spain and Galicia) and northern Italy (Verona) summing up a total of 1240 individuals. We also compared the allele frequencies on our population samples with those previously published for other European populations.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of CYP2C9 polymorphisms in the south of Europe

et al. 2009

View full text Add to dashboard Cite

CYP2C9 is a major liver enzyme responsible of the metabolism of many clinically important drugs. The presence of CYP2C9 genetic polymorphisms has been associated with marked interindividual variability in its catalytic activity that could result in drug toxicity. Here we present frequencies of the most common CYP2C9 coding variants CYP2C9*2 (C430T) and CYP2C9*3 (A1075C) in representative samples of four regions from Spain (Basque Country, n ¼ 358; Catalonia, n ¼ 240; Central Spain, n ¼ 190 and Galicia, n ¼ 288) and one northern Italian region, (Verona, n ¼ 164), which range between 0.125 and 0.165 in the case of CYP2C9*2 and between 0.071 and 0.085 for CYP2C9*3. No significant differences between CYP2C9 allele frequencies were found comparing all the sampled populations. A more extensive comparative analysis using allele frequency data of populations widely spread over Europe was performed, showing significant differences in the CYP2C9*2 allele frequencies distribution between some of the regions, being quite homogeneous in the case of CYP2C9*3 variant. The results obtained show that above 40% of our samples carry a mutate allele, which can result in a poor metabolization of low therapeutic index drugs as oral anticoagulants (warfarin, acenocoumarol), oral antidiabetic drugs and some non-steroidal anti-inflammatory drugs. Our study constitutes both a large (n ¼ 1240) and robust allele frequency database on CYP2C9 polymorphisms, which represents one of the most numerous CYP2C9*2 and *3 database existing to date.

show abstract

“…Even though our study is limited to the most important CYP alleles (SNPs) and a relatively small sample, it clearly the following frequencies: France 8.0 %, Belgium 7.4 %, Hungary 8.8 %, Croatia 9.5 %, Greece 8.1 %, and Macedonia 7.3 % (14,15,23,(26)(27)(28)..…”

Section: Resultsmentioning

confidence: 99%

Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population

Krasniqi

Dimovski

Bytyqi

et al. 2017

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

Cytochrome P450 genetic polymorphisms are responsible for individual variations in drug metabolism and drug-drug interactions. They are very important for pharmacogenetics, and their frequency varies across different populations. There is a big gap in the knowledge about the CYP gene family polymorphisms in the population of Kosovo, and the aim of our study was to fill that gap by determining the frequency of the most important variant alleles of CYP2C9, CYP2C19, and CYP3A5 in 234 nonrelated Kosovars. The allele frequencies of CYP2C9*2 and 2C9*3 were 17.52 %, and 10.89 %, respectively. Sixteen participants (6.81 %) were CYP2C9 poor metabolisers. The CYP2C19*2 and *17 variant frequencies were 13.03 % and 19.01 %, respectively. There were 2.13 % CYP2C19 poor and 4.27 % ultra-rapid metabolisers (homozygous carriers of the *17 allele). With regard to CYP3A5, the frequency of the *3 variant allele was 98.29 % (non-expressors), while the remaining participants (1.70 %) were expressors of CYP3A5. These findings are comparable with other European ethnicities, specifically those of Southeast Europe. KEY WORDS: cytochrome P450 enzyme system; drug metabolism; pharmacogeneticsIndividual variability in response to the most common drugs presents one of the major challenges to pharmacotherapy today. This variability depends on a variety of factors (drug interactions, hepatorenal disorders, sex, age, and lifestyle), but the most challenging are the genetic polymorphisms that have a direct and important impact on drug-detoxifying enzymes, drug targets, and drug transporters (1-3). Phase I enzymes metabolise nearly 59 % of the drugs reported for adverse drug reactions (ADR), and cytochromes P450 (CYP450 or CYP) make 75-86 % of these phase I enzymes (2, 4). Their genetic variants are responsible for unintended drug metabolism and interactions (5) that can lead to toxicity or failed pharmacotherapy (6). This has been recognised by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as both push policies requiring that pharmacogenetic information is provided for drug development and postmarketing surveillance (7,8).The most important genetic variants of CYP in clinical practice include those of CYP2C9, CYP2C19, and CYP3A5. Their frequencies vary across populations, and mapping them, so to speak, can be very useful in designing specific pharmacotherapy. To the best of our knowledge no such mapping has been done for the population of Kosovo, a southeast European country of over 1.7 million people, 93 % of whom are ethnic Albanians. The aim of our study was to address this gap and determine the frequency of the pharmacologically most important variant alleles of CYP2C9, CYP2C19, and CYP3A5 in Kosovo population, hoping that our findings could help to optimise pharmacotherapy in the country. PARTICIPANTS AND METHODSThis study included a mixed population of 234 randomly selected Caucasians (116 women and 118 men) with no blood relation from all parts of Kosovo. Their age ranged between 18 and 65 years (median: 3...

show abstract

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations

Cited by 100 publications

References 20 publications

Genetic polymorphism of CYP2C19 in Maharashtrian population

Genetic polymorphism of CYP2C19 in Maharashtrian population

Prevalence of CYP2C9 polymorphisms in the south of Europe

Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population

Contact Info

Product

Resources

About